Progress in the treatment of triple-negative breast cancer
https://www.facingourrisk.org/XRAY/treatment-of-triple-negative-breast-cancer
During the December 2023 San Antonio Breast Cancer Symposium, Dr. Melinda Telli presented a summary of research that has led to better treatments for triple-negative breast cancer (TNBC). These treatments now include drugs called targeted therapies and immunotherapies for both early and late stages of TNBC. (Posted 3/19/24)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- What are my treatment options for TNBC?
- Was my tumor tested for HER2 using a test that measures HER2-low? If yes, what was the HER2 score? If not, can it be tested now?
- What side effects can I expect from treatment?
Open Clinical Trials
The following are studies enrolling people with early-stage, TNBC.
- NCT05629585: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03). The study will look at how safe and effective the investigational drug Dato-DXd is with or without durvalumab when compared with the combination capecitabine and/or pembrolizumab in people with stage I to III TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
- NCT04584255: Treating Early-Stage BRCA, or PALB2-Associated Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab). This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA mutations.
- NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer.
- NCT03562637: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC. The GLORIA study is a Phase III, randomized trial looking at the use of the drug adagloxad simolenin (OBI-822) in combination with the drug OBI-821 in the adjuvant treatment of patients with high-risk early-stage TNBC.
- NCT05455658: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer. This trial studies the effect of a vaccine (STEMVAC) to treat patients with patients with stage IB-III triple negative breast cancer.
- NCT05929768: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer. This study compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer.
A number of other clinical trials for patients with early-stage TNBC can be found here.
The following are studies looking at new treatments for people with metastatic TNBC.
- NCT03606967: Testing the Addition of an Individual Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer. This study will look at how well the combination of chemotherapy, immunotherapy and targeted therapy when used with or without a vaccine made specifically for each patient.
- NCT04468061: Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic TNBC. This early phase study is looking at how safe and effective Trodelvy with or without Pembrolizumab is in patients who have TNBC that has spread to other parts of the body.
- NCT04020575: Using a Type of Immunotherapy Called CAR-T to Treat Metastatic Triple-Negative Breast Cancer. This study will look at how safe and how well a type of treatment made from the patient's cancer works for treatment certain types of metastatic breast cancer.
- NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent TNBC (InCITe). This studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating metastatic TNBC that has recurred.
- NCT04837209. Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer.
- NCT05081492: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer. This study is looking at the safety, side effects, and best dose of a drug called CF33-hNIS-antiPDL1 in treating patients with metastatic triple negative breast cancer. CF33-hNIS-antiPDL1 is a virus that is designed to attack and kill cancer cells.
A number of other clinical trials for treating patients with metastatic TNBC can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.